Clover Health Investments (CLOV) Stock Forecast, Price Target & Predictions
CLOV Stock Forecast
Clover Health Investments stock forecast is as follows: an average price target of $2.15 (represents a -50.35% downside from CLOV’s last price of $4.33) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
CLOV Price Target
The average price target for Clover Health Investments (CLOV) is $2.15 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $2.50 to $1.80. This represents a potential -50.35% downside from CLOV's last price of $4.33.
CLOV Analyst Ratings
According to 5 Wall Street analysts, Clover Health Investments's rating consensus is 'Hold'. The analyst rating breakdown for CLOV stock is 0 'Strong Buy' (0.00%), 1 'Buy' (20.00%), 4 'Hold' (80.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Clover Health Investments Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 06, 2024 | Richard Close | Canaccord Genuity | $2.50 | $1.86 | 34.32% | -42.26% |
| Nov 16, 2022 | - | Citigroup | $1.80 | $1.44 | 25.00% | -58.43% |
The latest Clover Health Investments stock forecast, released on Aug 06, 2024 by Richard Close from Canaccord Genuity, set a price target of $2.50, which represents a 34.32% increase from the stock price at the time of the forecast ($1.86), and a -42.26% decrease from CLOV last price ($4.33).
Clover Health Investments Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $2.50 | $2.50 |
| Last Closing Price | $4.33 | $4.33 | $4.33 |
| Upside/Downside | -100.00% | -42.26% | -42.26% |
In the current month, the average price target of Clover Health Investments stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Clover Health Investments's last price of $4.33. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 07, 2024 | UBS | - | Neutral | Initialise |
| Aug 06, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Nov 16, 2022 | Citigroup | Neutral | Neutral | Hold |
| Aug 09, 2022 | Citigroup | Neutral | Neutral | Hold |
| Aug 09, 2022 | Credit Suisse | Underperform | Underperform | Hold |
| May 10, 2022 | SVB Leerink | Market Perform | Market Perform | Hold |
| May 10, 2022 | Cowen & Co. | Market Perform | Market Perform | Hold |
| Feb 25, 2022 | SVB Leerink | Market Perform | Market Perform | Hold |
Clover Health Investments's last stock rating was published by UBS on Oct 07, 2024. The company Initialise its CLOV rating from "null" to "Neutral".
Clover Health Investments Financial Forecast
Clover Health Investments Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $510.25M | $482.07M | - | $527.77M | $898.79M | $856.82M | $846.70M | $874.38M | $432.04M | $427.16M | $412.47M | $200.32M | $-506.65M |
| Avg Forecast | $448.63M | $452.28M | $462.84M | $457.42M | $375.07M | $376.96M | $385.82M | $379.64M | $343.87M | $346.28M | $338.76M | $321.23M | $474.01M | $494.59M | $490.82M | $498.73M | $785.48M | $799.47M | $814.61M | $787.43M | $408.13M | $413.10M | $205.39M | $192.59M | $166.96M |
| High Forecast | $448.63M | $452.28M | $462.84M | $457.42M | $375.07M | $376.96M | $385.82M | $379.64M | $343.87M | $346.28M | $338.76M | $321.23M | $474.01M | $495.16M | $490.82M | $498.73M | $785.48M | $799.47M | $814.61M | $787.43M | $408.13M | $413.10M | $205.39M | $192.59M | $166.96M |
| Low Forecast | $448.63M | $452.28M | $462.84M | $457.42M | $375.07M | $376.96M | $385.82M | $379.64M | $343.87M | $346.28M | $338.76M | $321.23M | $474.01M | $494.02M | $490.82M | $498.73M | $785.48M | $799.47M | $814.61M | $787.43M | $408.13M | $413.10M | $205.39M | $192.59M | $166.96M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 0.97% | - | 1.06% | 1.14% | 1.07% | 1.04% | 1.11% | 1.06% | 1.03% | 2.01% | 1.04% | -3.03% |
Clover Health Investments's average Quarter revenue forecast for Mar 24 based on 1 analysts is $321.23M, with a low forecast of $321.23M, and a high forecast of $321.23M. CLOV's average Quarter revenue forecast represents a -37.05% decrease compared to the company's last Quarter revenue of $510.25M (Dec 23).
Clover Health Investments EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-64.99M | $-40.91M | - | $-72.33M | $-107.16M | $-73.30M | $-101.96M | $-86.47M | $-185.94M | $-33.98M | $-316.26M | $-33.42M | $20.01M |
| Avg Forecast | $-104.00M | $-104.85M | $-107.30M | $-106.04M | $-86.95M | $-87.39M | $-89.44M | $-88.01M | $-79.72M | $-80.27M | $-78.53M | $-83.95M | $-109.88M | $-114.66M | $-113.78M | $-89.79M | $-161.56M | $-185.33M | $-188.84M | $-96.03M | $-94.61M | $-95.76M | $-204.64M | $-44.65M | $-38.70M |
| High Forecast | $-104.00M | $-104.85M | $-107.30M | $-106.04M | $-86.95M | $-87.39M | $-89.44M | $-88.01M | $-79.72M | $-80.27M | $-78.53M | $-67.16M | $-109.88M | $-114.52M | $-113.78M | $-71.83M | $-129.25M | $-185.33M | $-188.84M | $-76.82M | $-94.61M | $-95.76M | $-163.71M | $-44.65M | $-38.70M |
| Low Forecast | $-104.00M | $-104.85M | $-107.30M | $-106.04M | $-86.95M | $-87.39M | $-89.44M | $-88.01M | $-79.72M | $-80.27M | $-78.53M | $-100.74M | $-109.88M | $-114.79M | $-113.78M | $-107.75M | $-193.87M | $-185.33M | $-188.84M | $-115.24M | $-94.61M | $-95.76M | $-245.56M | $-44.65M | $-38.70M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.59% | 0.36% | - | 0.81% | 0.66% | 0.40% | 0.54% | 0.90% | 1.97% | 0.35% | 1.55% | 0.75% | -0.52% |
1 analysts predict CLOV's average Quarter EBITDA for Mar 21 to be $-44.65M, with a high of $-44.65M and a low of $-44.65M. This is -323.11% lower than Clover Health Investments's previous annual EBITDA (Dec 20) of $20.01M.
Clover Health Investments Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-41.47M | - | $-72.61M | $-61.63M | $-76.29M | $-105.41M | $-62.91M | $-187.61M | $-34.53M | $-317.61M | $-48.42M | $3.26M |
| Avg Forecast | $-27.13M | $-5.41M | $-5.01M | $-8.84M | $-35.31M | $-13.52M | $-3.16M | $-19.98M | $-31.03M | $-19.95M | $-23.66M | $-85.34M | $-67.96M | $-51.47M | $-67.63M | $-91.28M | $-162.66M | $-109.33M | $-96.02M | $-97.62M | $-126.04M | $-111.48M | $-205.51M | $-53.29M | $-416.81M |
| High Forecast | $-27.13M | $-5.41M | $-5.01M | $-8.84M | $-35.31M | $-13.52M | $-3.16M | $-19.98M | $-31.03M | $-19.95M | $-23.66M | $-68.28M | $-67.96M | $-51.47M | $-67.63M | $-73.02M | $-130.13M | $-109.33M | $-96.02M | $-78.10M | $-126.04M | $-111.48M | $-164.41M | $-53.29M | $-416.81M |
| Low Forecast | $-27.13M | $-5.41M | $-5.01M | $-8.84M | $-35.31M | $-13.52M | $-3.16M | $-19.98M | $-31.03M | $-19.95M | $-23.66M | $-102.41M | $-67.96M | $-51.47M | $-67.63M | $-109.53M | $-195.19M | $-109.33M | $-96.02M | $-117.15M | $-126.04M | $-111.48M | $-246.62M | $-53.29M | $-416.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | - | 0.80% | 0.38% | 0.70% | 1.10% | 0.64% | 1.49% | 0.31% | 1.55% | 0.91% | -0.01% |
Clover Health Investments's average Quarter net income forecast for Mar 21 is $-53.29M, with a range of $-53.29M to $-53.29M. CLOV's average Quarter net income forecast represents a -1736.64% decrease compared to the company's last Quarter net income of $3.26M (Dec 20).
Clover Health Investments SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $45.98M | $41.75M | - | $129.42M | $124.35M | $117.97M | $117.53M | $126.79M | $114.21M | $119.11M | $107.80M | $104.63M | $54.56M |
| Avg Forecast | $121.32M | $122.31M | $125.16M | $123.70M | $101.43M | $101.94M | $104.34M | $102.66M | $92.99M | $93.64M | $91.61M | $143.68M | $128.18M | $133.75M | $132.73M | $153.67M | $99.23M | $216.19M | $220.29M | $164.35M | $110.37M | $111.71M | $69.75M | $52.08M | $45.15M |
| High Forecast | $121.32M | $122.31M | $125.16M | $123.70M | $101.43M | $101.94M | $104.34M | $102.66M | $92.99M | $93.64M | $91.61M | $172.42M | $128.18M | $133.90M | $132.73M | $184.41M | $119.08M | $216.19M | $220.29M | $197.23M | $110.37M | $111.71M | $83.70M | $52.08M | $45.15M |
| Low Forecast | $121.32M | $122.31M | $125.16M | $123.70M | $101.43M | $101.94M | $104.34M | $102.66M | $92.99M | $93.64M | $91.61M | $114.95M | $128.18M | $133.60M | $132.73M | $122.94M | $79.39M | $216.19M | $220.29M | $131.48M | $110.37M | $111.71M | $55.80M | $52.08M | $45.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.36% | 0.31% | - | 0.84% | 1.25% | 0.55% | 0.53% | 0.77% | 1.03% | 1.07% | 1.55% | 2.01% | 1.21% |
Clover Health Investments's average Quarter SG&A projection for Mar 24 is $143.68M, based on 1 Wall Street analysts, with a range of $114.95M to $172.42M. The forecast indicates a 212.47% rise compared to CLOV last annual SG&A of $45.98M (Dec 23).
Clover Health Investments EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.09 | - | $-0.15 | $-0.13 | $-0.16 | $-0.22 | $-0.13 | $-0.40 | $-0.08 | $-0.78 | $-0.13 | $-0.20 |
| Avg Forecast | $-0.06 | $-0.01 | $-0.01 | $-0.02 | $-0.07 | $-0.03 | $-0.01 | $-0.04 | $-0.06 | $-0.04 | $-0.05 | $-0.07 | $-0.14 | $-0.11 | $-0.14 | $-0.17 | $-0.24 | $-0.22 | $-0.20 | $-0.27 | $-0.26 | $-0.23 | $-0.14 | $-0.11 | $-0.86 |
| High Forecast | $-0.06 | $-0.01 | $-0.01 | $-0.02 | $-0.07 | $-0.03 | $-0.01 | $-0.04 | $-0.06 | $-0.04 | $-0.05 | $-0.07 | $-0.14 | $-0.11 | $-0.14 | $-0.17 | $-0.24 | $-0.22 | $-0.20 | $-0.27 | $-0.26 | $-0.23 | $-0.14 | $-0.11 | $-0.86 |
| Low Forecast | $-0.06 | $-0.01 | $-0.01 | $-0.02 | $-0.07 | $-0.03 | $-0.01 | $-0.04 | $-0.06 | $-0.04 | $-0.05 | $-0.07 | $-0.14 | $-0.11 | $-0.14 | $-0.17 | $-0.24 | $-0.22 | $-0.20 | $-0.27 | $-0.26 | $-0.23 | $-0.14 | $-0.11 | $-0.86 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.82% | - | 0.90% | 0.54% | 0.71% | 1.12% | 0.48% | 1.55% | 0.36% | 5.69% | 1.19% | 0.24% |
According to undefined Wall Street analysts, Clover Health Investments's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CLOV previous annual EPS of $NaN (undefined).
Clover Health Investments Peer Comparison by Price Target
CLOV Forecast FAQ
Is Clover Health Investments a good buy?
No, according to 5 Wall Street analysts, Clover Health Investments (CLOV) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 20.00% of CLOV's total ratings.
What is CLOV's price target?
Clover Health Investments (CLOV) average price target is $2.15 with a range of $1.8 to $2.5, implying a -50.35% from its last price of $4.33. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Clover Health Investments stock go up soon?
According to Wall Street analysts' prediction for CLOV stock, the company can go down by -50.35% (from the last price of $4.33 to the average price target of $2.15), down by -42.26% based on the highest stock price target, and down by -58.43% based on the lowest stock price target.
Can Clover Health Investments stock reach $6?
CLOV's average twelve months analyst stock price target of $2.15 does not support the claim that Clover Health Investments can reach $6 in the near future.
What are Clover Health Investments's analysts' financial forecasts?
Clover Health Investments's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.52B (high $1.52B, low $1.52B), average EBITDA is $-352M (high $-352M, low $-352M), average net income is $-71.973M (high $-71.973M, low $-71.973M), average SG&A $410.36M (high $410.36M, low $410.36M), and average EPS is $-0.148 (high $-0.148, low $-0.148). CLOV's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.82B (high $1.82B, low $1.82B), average EBITDA is $-422M (high $-422M, low $-422M), average net income is $-46.39M (high $-46.39M, low $-46.39M), average SG&A $492.48M (high $492.48M, low $492.48M), and average EPS is $-0.0952 (high $-0.0952, low $-0.0952).
Did the CLOV's actual financial results beat the analysts' financial forecasts?
Based on Clover Health Investments's last annual report (Dec 2023), the company's revenue was $2.03B, beating the average analysts forecast of $1.96B by 3.86%. Apple's EBITDA was $-206M, missing the average prediction of $-428M by -51.87%. The company's net income was $-213M, missing the average estimation of $-278M by -23.34%. Apple's SG&A was $187.57M, missing the average forecast of $548.33M by -65.79%. Lastly, the company's EPS was $-0.44, missing the average prediction of $-0.55 by -20.03%. In terms of the last quarterly report (Dec 2023), Clover Health Investments's revenue was $510.25M, beating the average analysts' forecast of $474.01M by 7.65%. The company's EBITDA was $-64.986M, missing the average prediction of $-110M by -40.86%. Clover Health Investments's net income was $0, missing the average estimation of $-67.955M by -100.00%. The company's SG&A was $45.98M, missing the average forecast of $128.18M by -64.13%. Lastly, the company's EPS was $0, missing the average prediction of $-0.139 by -100.00%